title: Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
abstract: The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first-line treatment, data on allogeneic hematopoietic stem cell transplantation (allo SCT) as second-line therapy after imatinib failure are scarce. Using an interim safety analysis of the randomized German CML Study IV designed to optimize imatinib therapy by combination, dose escalation, and transplantation, we here report on 84 patients who underwent consecutive transplantation according to predefined criteria (low European Group for Blood and Marrow Transplantation [EBMT] score, imatinib failure, and advanced disease). Three-year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up: 30 months). Transplantation-related mortality was 8%. In a matched pair comparison of patients who received a transplant and those who did not, survival was not different. Three-year survival after transplantation of 28 patients in advanced phase was 59%. Eighty-eight percent of patients who received a transplant achieved complete molecular remissions. We conclude that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institutes of Health, http://clinicaltrials.gov: NCT00055874.
authors: III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
authors: Susanne
authors: S
authors: Saussele
authors: Michael
authors: M
authors: Lauseker
authors: Alois
authors: A
authors: Gratwohl
authors: Dietrich W
authors: DW
authors: Beelen
authors: Donald
authors: D
authors: Bunjes
authors: Rainer
authors: R
authors: Schwerdtfeger
authors: Hans-Jochem
authors: HJ
authors: Kolb
authors: Anthony D
authors: AD
authors: Ho
authors: Christiane
authors: C
authors: Falge
authors: Ernst
authors: E
authors: Holler
authors: Günter
authors: G
authors: Schlimok
authors: Axel R
authors: AR
authors: Zander
authors: Renate
authors: R
authors: Arnold
authors: Lothar
authors: L
authors: Kanz
authors: Robert
authors: R
authors: Dengler
authors: Claudia
authors: C
authors: Haferlach
authors: Brigitte
authors: B
authors: Schlegelberger
authors: Markus
authors: M
authors: Pfirrmann
authors: Martin C
authors: MC
authors: Müller
authors: Susanne
authors: S
authors: Schnittger
authors: Armin
authors: A
authors: Leitner
authors: Nadine
authors: N
authors: Pletsch
authors: Andreas
authors: A
authors: Hochhaus
authors: Joerg
authors: J
authors: Hasford
authors: Rüdiger
authors: R
authors: Hehlmann
mesh_terms: D000328:Adult; D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D003561:Cytarabine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D005858:Germany; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007372:Interferons / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate; D007372:Interferons